GR3017432T3 - Stabilization of therapeutically active proteins in pharmaceutical preparations. - Google Patents

Stabilization of therapeutically active proteins in pharmaceutical preparations.

Info

Publication number
GR3017432T3
GR3017432T3 GR950402557T GR950402557T GR3017432T3 GR 3017432 T3 GR3017432 T3 GR 3017432T3 GR 950402557 T GR950402557 T GR 950402557T GR 950402557 T GR950402557 T GR 950402557T GR 3017432 T3 GR3017432 T3 GR 3017432T3
Authority
GR
Greece
Prior art keywords
pharmaceutical preparations
therapeutically active
stabilization
active proteins
proteins
Prior art date
Application number
GR950402557T
Other languages
English (en)
Inventor
Traute Dr Mundorf
Kurt Dr Schnecker
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of GR3017432T3 publication Critical patent/GR3017432T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GR950402557T 1987-09-17 1995-09-18 Stabilization of therapeutically active proteins in pharmaceutical preparations. GR3017432T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873731255 DE3731255A1 (de) 1987-09-17 1987-09-17 Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen

Publications (1)

Publication Number Publication Date
GR3017432T3 true GR3017432T3 (en) 1995-12-31

Family

ID=6336244

Family Applications (1)

Application Number Title Priority Date Filing Date
GR950402557T GR3017432T3 (en) 1987-09-17 1995-09-18 Stabilization of therapeutically active proteins in pharmaceutical preparations.

Country Status (20)

Country Link
EP (1) EP0307857B1 (el)
JP (1) JP2783552B2 (el)
KR (1) KR970008112B1 (el)
AT (1) ATE126063T1 (el)
AU (1) AU615473B2 (el)
CA (1) CA1329121C (el)
DD (1) DD274562A5 (el)
DE (2) DE3731255A1 (el)
DK (1) DK516288A (el)
ES (1) ES2077559T3 (el)
FI (1) FI95770C (el)
GR (1) GR3017432T3 (el)
HU (1) HU203045B (el)
IE (1) IE70908B1 (el)
IL (1) IL87778A (el)
NO (1) NO179436C (el)
NZ (1) NZ226209A (el)
PT (1) PT88539B (el)
RU (1) RU2093145C1 (el)
ZA (1) ZA886903B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5324521A (en) * 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
JPH0776527A (ja) * 1993-06-28 1995-03-20 Hayashibara Biochem Lab Inc 半固形製剤とその製造方法
ITMI20031640A1 (it) * 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
NZ603479A (en) 2010-05-04 2014-07-25 Viscogel Ab Chitosan composition
WO2018231863A1 (en) * 2017-06-12 2018-12-20 Lakewood Amedex, Inc Bisphosphocin gel formulations and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5413223A (en) * 1977-07-01 1979-01-31 Ricoh Co Ltd Printer unit
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5892622A (ja) * 1981-11-28 1983-06-02 Sunstar Inc インタ−フエロン安定配合製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
JPS6061535A (ja) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト 製薬学的組成物
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
PT88539B (pt) 1992-11-30
PT88539A (pt) 1988-10-01
EP0307857A1 (de) 1989-03-22
AU615473B2 (en) 1991-10-03
KR970008112B1 (ko) 1997-05-21
DE3731255A1 (de) 1989-04-06
JPH01102029A (ja) 1989-04-19
JP2783552B2 (ja) 1998-08-06
NO884123D0 (no) 1988-09-16
FI884240A (fi) 1989-03-18
IL87778A (en) 1993-05-13
EP0307857B1 (de) 1995-08-09
NO179436B (no) 1996-07-01
IE70908B1 (en) 1997-01-15
FI95770C (fi) 1996-03-25
NO179436C (no) 1996-10-09
KR890004719A (ko) 1989-05-09
NZ226209A (en) 1991-06-25
DK516288A (da) 1989-03-18
HUT47436A (en) 1989-03-28
NO884123L (no) 1989-03-20
FI884240A0 (fi) 1988-09-15
ES2077559T3 (es) 1995-12-01
HU203045B (en) 1991-05-28
AU2231688A (en) 1989-03-23
CA1329121C (en) 1994-05-03
ATE126063T1 (de) 1995-08-15
RU2093145C1 (ru) 1997-10-20
ZA886903B (en) 1990-05-30
DK516288D0 (da) 1988-09-16
FI95770B (fi) 1995-12-15
IL87778A0 (en) 1989-03-31
DD274562A5 (de) 1989-12-27
IE882812L (en) 1989-03-17
DE3854290D1 (de) 1995-09-14

Similar Documents

Publication Publication Date Title
ATE91903T1 (de) Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.
ZA885192B (en) Pharmaceutical preparations
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
AU610636B2 (en) Stabilised human protein preparations
DK653688A (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
DK642587A (da) Insulinpraeparat
EP0283713A3 (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
EP0177342A3 (en) Oral formulation of therapeutic proteins
GR3017432T3 (en) Stabilization of therapeutically active proteins in pharmaceutical preparations.
EP0370481A3 (de) Pharmazeutische Präparate zur verbesserten Resorption antibakterieller Verbindungen
PT996462E (pt) Preparados de combinacoes farmaceuticas contendo eritropoietina e hemoglobinas modificadas
TW290455B (el)
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
EP0265338A3 (en) Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
GR3032639T3 (en) Vehicles for oral adminstration of pharmaceutically active acide labile substances.